<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646162</url>
  </required_header>
  <id_info>
    <org_study_id>V72203</org_study_id>
    <nct_id>NCT03646162</nct_id>
  </id_info>
  <brief_title>Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer</brief_title>
  <official_title>Randomized, Double-blind, Placebo Controlled, Dose Finding Phase 2 Study Comparing Oral Daily Dosing of VERU-944 to Ameliorate the Vasomotor Symptoms Resulting From ADT in Men With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veru Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veru Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily&#xD;
      dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the&#xD;
      vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate&#xD;
      cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, double-blind, placebo controlled, dose finding study&#xD;
      of VERU-944 to treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on&#xD;
      ADT. The study will have four arms with 30 subjects per arm. The subjects participating in&#xD;
      the study will have advanced prostate cancer and will be undergoing androgen deprivation&#xD;
      therapy (ADT) with a luteinizing hormone releasing hormone (LHRH) therapy (agonist or&#xD;
      antagonist) for at least the three months prior to randomization and be experiencing regular&#xD;
      moderate to severe hot flashes while on ADT. Subjects will all continue to receive ADT and&#xD;
      will be randomized to receive, for the first four days, a loading dose followed by daily&#xD;
      doses of placebo or VERU-944 (10 mg, 50 mg or 100 mg) orally for a total period of 12 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Percentage change in frequency of moderate to severe hot flashes at 6 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Severity of Moderate to Severe Hot Flashes at 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Change in severity of moderate to severe hot flashes compared to baseline at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Frequency of Moderate to Severe Hot Flashes at Weeks 4,8,10 and 12</measure>
    <time_frame>Weeks 4,8,10 and 12</time_frame>
    <description>Mean change in frequency of moderate to severe hot flashes compared to baseline at weeks 4,8,10 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Severity of Moderate to Severe Hot Flashes at Weeks 4,8.10 and 12</measure>
    <time_frame>Weeks 4,8,10 and 12</time_frame>
    <description>Mean change in severity of moderate to severe hot flashes compared to baseline at weeks 4,8,10 and12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Turnover Markers C-telopeptide (CTX)</measure>
    <time_frame>84 days</time_frame>
    <description>Change in C-telopeptide concentration at day 84 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Turnover Markers Alkaline Phosphatase</measure>
    <time_frame>84 days</time_frame>
    <description>Change in bone specific alkaline phosphatase at day 84 compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Serum PSA</measure>
    <time_frame>84 Days</time_frame>
    <description>Change in serum PSA concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Total Testosterone</measure>
    <time_frame>84 Days</time_frame>
    <description>Change in serum total testosterone concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum Free Testosterone</measure>
    <time_frame>84 days</time_frame>
    <description>Change in serum free testosterone concentration comparing baseline to day 84</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Serum SHBG</measure>
    <time_frame>84 days</time_frame>
    <description>Change in serum SHBG concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Sess Safety</measure>
    <time_frame>114 days</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events will be tabulated by MedDRA terms and system organ class. The incidence of AEs and the maximum intensity and frequency of AEs will be summarized. The intensity of AE will be graded according to CTCAE version 4. Changes from baseline will be computed and tested for significant change from baseline to day 114</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Veru-944 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veru-944 10 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Veru-944 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veru-944 50 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Veru-944</intervention_name>
    <description>Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
    <arm_group_label>Veru-944 10 mg</arm_group_label>
    <arm_group_label>Veru-944 50 mg</arm_group_label>
    <other_name>Zuclomiphene citrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Be over 18 years of age;&#xD;
&#xD;
          2. Be able to communicate effectively with the study personnel;&#xD;
&#xD;
          3. Have histologically confirmed prostate cancer;&#xD;
&#xD;
          4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months&#xD;
             prior to randomization;&#xD;
&#xD;
          5. Be continued on an LHRH agonist or LHRH antagonist throughout this study;&#xD;
&#xD;
          6. Have experienced hot flashes for at least one month prior to study entry;&#xD;
&#xD;
          7. Have moderate or severe vasomotor symptoms (hot flashes) (defined as a minimum of 4&#xD;
             moderate to severe hot flashes per day or 12 per week at baseline);&#xD;
&#xD;
          8. ECOG performance status of 0 to 2&#xD;
&#xD;
          9. Be willing to uses electronic data capture for the relevant medical events&#xD;
&#xD;
             â€¢ Must be at least 80% compliant during the screening period&#xD;
&#xD;
         10. Subjects must agree to use acceptable methods of contraception:&#xD;
&#xD;
               -  If their female partners are pregnant or lactating, acceptable methods of&#xD;
                  contraception from the time of the first administration of study medication until&#xD;
                  6 months following administration of the last dose of study medication must be&#xD;
                  used. Acceptable methods are: Condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository. If the subject has undergone surgical&#xD;
                  sterilization (vasectomy with documentation of azospermia), a condom with&#xD;
                  spermicidal foam/gel/film/cream/suppository should be used.&#xD;
&#xD;
               -  If the male subject's partner could become pregnant, use acceptable methods of&#xD;
                  contraception from the time of the first administration of study medication until&#xD;
                  6 months following administration of the last dose of study medication.&#xD;
                  Acceptable methods of contraception are as follows: Condom with spermicidal&#xD;
                  foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical&#xD;
                  sterilization (vasectomy with documentation of azospermia) and a barrier method&#xD;
                  {condom used with spermicidal foam/gel/film/cream/suppository}, the female&#xD;
                  partner uses oral contraceptives (combination estrogen/progesterone pills),&#xD;
                  injectable progesterone or subdermal implants and a barrier method (condom used&#xD;
                  with spermicidal foam/gel/film/cream/suppository).&#xD;
&#xD;
               -  If the female partner has undergone documented tubal ligation (female&#xD;
                  sterilization), a barrier method (condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository) should also be used.&#xD;
&#xD;
               -  If the female partner has undergone documented placement of an intrauterine&#xD;
                  device (IUD) or intrauterine system (IUS), a barrier method (condom with&#xD;
                  spermicidal foam/gel/film/cream/suppository) should also be used.&#xD;
&#xD;
         11. Subject is willing to comply with the requirements of the protocol through the end of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Have a serum total testosterone concentration &gt; 50 ng/dL at screening;&#xD;
&#xD;
          2. Known hypersensitivity or allergy to estrogen or estrogen like drugs;&#xD;
&#xD;
          3. Any disease or condition (medical or surgical) which might compromise the hematologic,&#xD;
             cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic, or central&#xD;
             nervous system; or other conditions that may interfere with the absorption,&#xD;
             distribution, metabolism or excretion of study drug, or would place the subject at&#xD;
             increased risk;&#xD;
&#xD;
          4. Subjects with a personal history of abnormal blood clotting or thrombotic disease,&#xD;
             including venous or arterial thrombotic events such as a history of stroke, deep vein&#xD;
             thrombosis (DVT), and/or pulmonary embolus (PE);&#xD;
&#xD;
          5. Any subjects, as determined by a central laboratory, that have a:&#xD;
&#xD;
               -  Factor V Leiden gene mutation&#xD;
&#xD;
               -  Prothrombin gene mutation&#xD;
&#xD;
          6. Uncontrolled symptomatic congestive heart failure (NYHA Class III - IV), unstable&#xD;
             angina pectoris, cardiac arrhythmia, or uncontrolled atrial fibrillation;&#xD;
&#xD;
          7. History of MI&#xD;
&#xD;
          8. The presence of consistently abnormal laboratory values which are considered&#xD;
             clinically significant. In addition, any subject with liver enzymes (ALT or AST) above&#xD;
             2 times the upper limit of normal, total bilirubin above 2 times the upper limit of&#xD;
             normal, or serum creatinine above 1.5 times the upper limit of normal will NOT be&#xD;
             admitted to the study;&#xD;
&#xD;
          9. Received an investigational drug within a period of 90 days prior to enrollment in the&#xD;
             study;&#xD;
&#xD;
         10. Received the study medication (VERU-944) previously;&#xD;
&#xD;
         11. Have previously taken within 6 months prior to screening or are currently taking&#xD;
             diethylstilbestrol, other estrogens;&#xD;
&#xD;
         12. Currently taking gabapentin, estrogen, diethylstilbestrol, medroxyprogesterone&#xD;
             acetate, clomiphene, selective serotonin reuptake inhibitors (SSRIs), other treatments&#xD;
             for hot flashes&#xD;
&#xD;
         13. Recent hospitalization for more than 24 hours (within 30 days of screening);&#xD;
&#xD;
         14. Recent surgery (within 30 days of screening);&#xD;
&#xD;
         15. Have been previously diagnosed or treated for active cancer (other than prostate&#xD;
             cancer or non-melanoma skin cancer) within the previous five years;&#xD;
&#xD;
         16. Have a BMI &gt;40.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Males</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barnette</last_name>
    <role>Study Chair</role>
    <affiliation>Veru Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gen1 Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of San Bernardino</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Urology</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universal Axon Clinical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Urology</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Urology LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Urology</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Urology Group</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08837</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advance Urology</name>
      <address>
        <city>Elmont</city>
        <state>New York</state>
        <zip>11003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Urology Partners</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <results_first_submitted>May 1, 2021</results_first_submitted>
  <results_first_submitted_qc>May 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03646162/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03646162/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Veru-944 10 mg</title>
          <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
        </group>
        <group group_id="P2">
          <title>Veru-944 50 mg</title>
          <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo daily&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Veru-944 10 mg</title>
          <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
        </group>
        <group group_id="B2">
          <title>Veru-944 50 mg</title>
          <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo daily&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.8" spread="5.79"/>
                    <measurement group_id="B2" value="70.6" spread="8.84"/>
                    <measurement group_id="B3" value="69.1" spread="8.05"/>
                    <measurement group_id="B4" value="70.2" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hot Flashes</title>
          <units>Percentage hot flashes moderate to se</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.5" spread="36.52"/>
                    <measurement group_id="B2" value="29.7" spread="22.2"/>
                    <measurement group_id="B3" value="33.7" spread="20.23"/>
                    <measurement group_id="B4" value="34.9" spread="26.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks</title>
        <description>Percentage change in frequency of moderate to severe hot flashes at 6 weeks</description>
        <time_frame>6 weeks</time_frame>
        <population>Percentage Change of hot flashes from baseline to week 6</population>
        <group_list>
          <group group_id="O1">
            <title>Veru-944 10 mg</title>
            <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O2">
            <title>Veru-944 50 mg</title>
            <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks</title>
          <description>Percentage change in frequency of moderate to severe hot flashes at 6 weeks</description>
          <population>Percentage Change of hot flashes from baseline to week 6</population>
          <units>percentage of hot flashes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.72" spread="8.840"/>
                    <measurement group_id="O2" value="-42.24" spread="8.196"/>
                    <measurement group_id="O3" value="-46.59" spread="7.760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Severity of Moderate to Severe Hot Flashes at 6 Weeks</title>
        <description>Change in severity of moderate to severe hot flashes compared to baseline at 6 weeks</description>
        <time_frame>6 weeks</time_frame>
        <population>Percentage change in severity of moderate to severe hot flashes compared to baseline at 6 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Veru-944 10 mg</title>
            <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O2">
            <title>Veru-944 50 mg</title>
            <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Severity of Moderate to Severe Hot Flashes at 6 Weeks</title>
          <description>Change in severity of moderate to severe hot flashes compared to baseline at 6 weeks</description>
          <population>Percentage change in severity of moderate to severe hot flashes compared to baseline at 6 weeks</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.386"/>
                    <measurement group_id="O2" value="-0.31" spread="0.416"/>
                    <measurement group_id="O3" value="-0.35" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Frequency of Moderate to Severe Hot Flashes at Weeks 4,8,10 and 12</title>
        <description>Mean change in frequency of moderate to severe hot flashes compared to baseline at weeks 4,8,10 and 12</description>
        <time_frame>Weeks 4,8,10 and 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Severity of Moderate to Severe Hot Flashes at Weeks 4,8.10 and 12</title>
        <description>Mean change in severity of moderate to severe hot flashes compared to baseline at weeks 4,8,10 and12</description>
        <time_frame>Weeks 4,8,10 and 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Turnover Markers C-telopeptide (CTX)</title>
        <description>Change in C-telopeptide concentration at day 84 compared to baseline</description>
        <time_frame>84 days</time_frame>
        <population>Change in C-telopeptide concentration at day 84 compared to baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Veru-944 10 mg</title>
            <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O2">
            <title>Veru-944 50 mg</title>
            <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Turnover Markers C-telopeptide (CTX)</title>
          <description>Change in C-telopeptide concentration at day 84 compared to baseline</description>
          <population>Change in C-telopeptide concentration at day 84 compared to baseline</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.7" spread="262"/>
                    <measurement group_id="O2" value="362.1" spread="305.44"/>
                    <measurement group_id="O3" value="466" spread="347.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Bone Turnover Markers Alkaline Phosphatase</title>
        <description>Change in bone specific alkaline phosphatase at day 84 compared to baseline</description>
        <time_frame>84 days</time_frame>
        <population>Change in bone specific alkaline phosphatase at day 84 compared to baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Veru-944 10 mg</title>
            <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O2">
            <title>Veru-944 50 mg</title>
            <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bone Turnover Markers Alkaline Phosphatase</title>
          <description>Change in bone specific alkaline phosphatase at day 84 compared to baseline</description>
          <population>Change in bone specific alkaline phosphatase at day 84 compared to baseline</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.89" spread="4.598"/>
                    <measurement group_id="O2" value="15.72" spread="22.468"/>
                    <measurement group_id="O3" value="13.12" spread="6.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum PSA</title>
        <description>Change in serum PSA concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
        <time_frame>84 Days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Total Testosterone</title>
        <description>Change in serum total testosterone concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
        <time_frame>84 Days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum Free Testosterone</title>
        <description>Change in serum free testosterone concentration comparing baseline to day 84</description>
        <time_frame>84 days</time_frame>
        <population>Change in serum free testosterone concentration comparing baseline to day 84</population>
        <group_list>
          <group group_id="O1">
            <title>Veru-944 10 mg</title>
            <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O2">
            <title>Veru-944 50 mg</title>
            <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Free Testosterone</title>
          <description>Change in serum free testosterone concentration comparing baseline to day 84</description>
          <population>Change in serum free testosterone concentration comparing baseline to day 84</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.895"/>
                    <measurement group_id="O2" value="1.38" spread="4.873"/>
                    <measurement group_id="O3" value="1.0" spread="1.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Serum SHBG</title>
        <description>Change in serum SHBG concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
        <time_frame>84 days</time_frame>
        <population>Change in serum SHBG concentration comparing baseline to day 84</population>
        <group_list>
          <group group_id="O1">
            <title>Veru-944 10 mg</title>
            <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O2">
            <title>Veru-944 50 mg</title>
            <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo daily&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum SHBG</title>
          <description>Change in serum SHBG concentration comparing baseline to day 30, baseline to day 60 and baseline to day 84 for each treatment group</description>
          <population>Change in serum SHBG concentration comparing baseline to day 84</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.7" spread="28.27"/>
                    <measurement group_id="O2" value="113.5" spread="60.53"/>
                    <measurement group_id="O3" value="54.1" spread="24.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Sess Safety</title>
        <description>Incidence of Treatment-Emergent Adverse Events will be tabulated by MedDRA terms and system organ class. The incidence of AEs and the maximum intensity and frequency of AEs will be summarized. The intensity of AE will be graded according to CTCAE version 4. Changes from baseline will be computed and tested for significant change from baseline to day 114</description>
        <time_frame>114 days</time_frame>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Post-hoc Analysis on the Percentage Change in Frequency of Moderate and Severe Hot Flashes From Baseline to Week 12; Exposure Response Assessment</title>
        <description>Post-hoc exploratory MMRM analysis was conducted to explore the effect of trough plasma concentration at Week12 on the change in frequency of moderate and severe hot flashes from Baseline to Week 12 in subjects with a BMI &gt;25 kg/m2.</description>
        <time_frame>Day 84</time_frame>
        <population>Subjects with a BMI &gt;25 kg/m2 who had trough plasma concentrations â‰¥195 ng/mL vs &lt;195 ng/mL Change in moderate and severe hot flash frequency at Week 12</population>
        <group_list>
          <group group_id="O1">
            <title>PK â‰¥195ng/mL</title>
            <description>Subjects who had trough plasma concentrations â‰¥195 ng/mL at Day 84 change in moderate and severe hot flash frequency at Week 12,</description>
          </group>
          <group group_id="O2">
            <title>PK &lt;195 ng/mL</title>
            <description>Subjects who had trough plasma concentrations &lt;195 ng/mL at Day 84 change in moderate and severe hot flash frequency at Week 12,</description>
          </group>
        </group_list>
        <measure>
          <title>Post-hoc Analysis on the Percentage Change in Frequency of Moderate and Severe Hot Flashes From Baseline to Week 12; Exposure Response Assessment</title>
          <description>Post-hoc exploratory MMRM analysis was conducted to explore the effect of trough plasma concentration at Week12 on the change in frequency of moderate and severe hot flashes from Baseline to Week 12 in subjects with a BMI &gt;25 kg/m2.</description>
          <population>Subjects with a BMI &gt;25 kg/m2 who had trough plasma concentrations â‰¥195 ng/mL vs &lt;195 ng/mL Change in moderate and severe hot flash frequency at Week 12</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.60" spread="14.542"/>
                    <measurement group_id="O2" value="-50.14" spread="5.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Veru-944 10 mg</title>
          <description>Veru-944 10 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
        </group>
        <group group_id="E2">
          <title>Veru-944 50 mg</title>
          <description>Veru-944 50 mg daily&#xD;
Veru-944: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo daily&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Atrial Fibrillation</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <description>Coronary Artery Disease</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Appendicitis</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>Anaemia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Neutropenia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Atrial Fibrillation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Coronary artery disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <description>Vision Blurred</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Constipation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <description>Dyspepsia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <description>Flatulence</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nauseas</sub_title>
                <description>Nauseas</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Abdominal Pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <description>Abdominal Pain Upper</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <description>Diarrhoea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <description>gastroesophageal Reflux Disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Fatigue</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <description>Oedema Peripheral</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <description>Peripheral Swelling</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Urinary Tract Infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Nasopharyngitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Appendicitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <description>Influenza</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Pneumonia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <description>Sinusitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <description>Tooth Infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <description>Upper Respiratory Tract Infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Fall</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <description>Cardiac Murmur</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <description>Low density lipoprotein increased</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Arthralgia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <description>Muscle Spasms</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <description>Arthritis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Back Pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Myalgia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Pain in extremity</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Balance Disorder</sub_title>
                <description>Balance Disorder</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <description>Burning sensation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <description>Disturbance in Attention</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Dizziness</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <description>Memory Impairment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Insomnia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Hematuria</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <description>Micturition urgency</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>Nephrolithiasis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <description>Nocturia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Post micturition dribble</sub_title>
                <description>Post micturition dribble</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal Mass</sub_title>
                <description>Renal Mass</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <description>Cough</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <description>Alopecia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gary Barnette PhD CSO</name_or_title>
      <organization>Veru</organization>
      <phone>9194263611</phone>
      <email>gbarnette@verupharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

